Ionis Pharmaceuticals (IONS) Q2 2025 earnings summary

Executive summary

• Achieved strong momentum and total revenue of $452M in Q2 2025, up 101% year-over-year, driven by the independent launch of TRYNGOLZA, major collaboration payments, and robust late-stage pipeline progress.

• TRYNGOLZA net sales reached $19M in Q2, with positive CHMP opinion in Europe and strong uptake among cardiologists and endocrinologists; >90% of patients paid $0 out of pocket.

• Anticipates FDA approval and launch of donidalorsen for hereditary angioedema in August 2025, with preparations and market education underway.

• Advancing late-stage pipeline with pivotal data for olezarsen (SHTG) and zilganersen (Alexander disease) expected in September 2025; multiple launches and milestones through 2027.

• Strong commercial execution, favorable payer dynamics, and ongoing launches are driving growth, with a focus on patient identification and education.

Financial highlights

• Q2 2025 total revenue: $452M, up from $225M in Q2 2024; H1 2025 revenue: $584M, up from $345M in H1 2024.

• Q2 2025 net income: $123.6M; H1 2025 net loss: $23.4M, improved from $209.1M loss in prior year.

• TRYNGOLZA product sales were $19M in Q2 and $26M in H1 2025; royalty revenues rose ~10% year-over-year, with significant contributions from SPINRAZA and WAINUA.

• R&D collaboration revenue included a $280M upfront payment for the olezarsen/sapablursen license and a $30M milestone from AstraZeneca.

• Operating expenses for Q2 2025: $312.2M, up from $291.3M in Q2 2024, reflecting increased SG&A for new launches; non-GAAP operating expenses increased 8% year-over-year.

Outlook and guidance

• 2025 revenue guidance raised to $825–$850M, driven by TRYNGOLZA performance and robust royalty streams; TRYNGOLZA product sales expected to reach $75–$80M in 2025.

• Operating loss projected at $300–$325M for 2025 (non-GAAP), with year-end cash balance of ~$2.0B.

• Donidalorsen approval anticipated in August, with modest revenue contribution in 2025 and greater impact in 2026.

• Multiple regulatory submissions and pivotal data readouts expected in 2025 and 2026, supporting sustained growth.

• Continued disciplined investment in launches and pipeline expected to drive positive cash flow in coming years.